Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study
Swaminathan P. Iyer(The University of Texas MD Anderson Cancer Center), Bradley M. Haverkos(University of Colorado Denver), Deepa Jagadeesh(University of Massachusetts Chan Medical School), Tatyana Feldman(Hackensack University Medical Center), Paola Ghione(University of Turin), Auris Huen(University of Pennsylvania), Seo‐Hyun Kim(Rush University Medical Center), Prajak J. Barde(Rhizen Pharmaceuticals (Switzerland)), Weiyun Z. Ai(City College of San Francisco), Juan Pablo Alderuccio(Sylvester Comprehensive Cancer Center), Mary Jo Lechowicz(Emory University), Craig Okada(Oregon Health & Science University), Ajit Nair(Rhizen Pharmaceuticals (Switzerland)), Rebecca Champion(Norton Healthcare), Ann Mohrbacher(University of Southern California), Kasi V. Routhu(Rhizen Pharmaceuticals (Switzerland))
Cited by 24
Related Papers
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
|Journal of Clinical Oncology|2010|487